These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27794527)

  • 1. The Challenges of Daratumumab in Transfusion Medicine.
    Dizon MF
    Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolving the daratumumab interference with blood compatibility testing.
    Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
    Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
    Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
    Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
    Ye Z; Wolf LA; Mettman D; Plapp FV
    Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
    De Vooght KM; Oostendorp M; van Solinge WW
    Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
    Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
    Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
    Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
    Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
    Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
    Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
    Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab.
    Disbro WL
    Immunohematology; 2017 Sep; 33(3):105-109. PubMed ID: 29043827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
    Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
    Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
    Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
    Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals.
    Youssef M; Arnesen C; Arledge C; Langley C; Sylvester D; Sikora J; Marques MB; Long Zheng X; Williams LA
    Transfus Apher Sci; 2019 Apr; 58(2):152-155. PubMed ID: 30639177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab: Therapeutic asset, biological trap!
    Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
    Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody incidence and red blood cell transfusions in patients on daratumumab.
    Tauscher C; Moldenhauer S; Bryant S; DiGuardo M; Jacob EK
    Transfusion; 2021 Dec; 61(12):3468-3472. PubMed ID: 34617617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of Daratumumab on transfusion service costs.
    Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
    Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
    Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
    Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference.
    Lintel NJ; Brown DK; Schafer DT; Tsimba-Chitsva FM; Koepsell SA; Shunkwiler SM
    Immunohematology; 2017 Jan; 33(1):22-26. PubMed ID: 28425752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.